Diagnostic biomarkers in ovarian cancer: advances beyond CA125 and HE4

A Ghose, L McCann, S Makker… - … in medical oncology, 2024‏ - journals.sagepub.com
Ovarian cancer (OC) is the most lethal gynaecologic malignancy, attributed to its insidious
growth, non-specific symptoms and late presentation. Unfortunately, current screening …

Proteomic applications for the early detection of cancer

JD Wulfkuhle, LA Liotta, EF Petricoin - Nature reviews cancer, 2003‏ - nature.com
The ability of physicians to effectively treat and cure cancer is directly dependent on their
ability to detect cancers at their earliest stages. Proteomic analyses of early-stage cancers …

Cancer-associated mesothelial cells promote ovarian cancer chemoresistance through paracrine osteopontin signaling

J Qian, BL LeSavage, KM Hubka, C Ma… - The Journal of Clinical …, 2021‏ - jci.org
Ovarian cancer is the leading cause of gynecological malignancy–related deaths, due to its
widespread intraperitoneal metastases and acquired chemoresistance. Mesothelial cells are …

[HTML][HTML] The response and resistance to drugs in ovarian cancer cell lines in 2D monolayers and 3D spheroids

M Świerczewska, K Sterzyńska, M Ruciński… - Biomedicine & …, 2023‏ - Elsevier
Ovarian cancer is the most common type of gynecologic cancer. One of the leading causes
of high mortality is chemoresistance, developed primarily or during treatment. Different …

The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass

RG Moore, AK Brown, MC Miller, S Skates… - Gynecologic …, 2008‏ - Elsevier
OBJECTIVES.: The CA125 tumor marker is used to help predict the presence of ovarian
cancer in patients with an adnexal mass. Because elevated CA125 levels occur in many …

National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian …

CM Sturgeon, MJ Duffy, UH Stenman, H Lilja… - 2008‏ - academic.oup.com
Abstract Background: Updated National Academy of Clinical Biochemistry (NACB)
Laboratory Medicine Practice Guidelines for the use of tumor markers in the clinic have been …

Osteopontin: a key regulator of tumor progression and immunomodulation

HR Moorman, D Poschel, JD Klement, C Lu, PS Redd… - Cancers, 2020‏ - mdpi.com
Simple Summary Anti-PD-1/PD-L1 and anti-CTLA-4-based immune checkpoint blockade
(ICB) immunotherapy have recently emerged as a breakthrough in human cancer treatment …

Molecular circuits shared by placental and cancer cells, and their implications in the proliferative, invasive and migratory capacities of trophoblasts

C Ferretti, L Bruni, V Dangles-Marie… - Human reproduction …, 2007‏ - academic.oup.com
Trophoblast research over the past decades has underlined the striking similarities between
the proliferative, migratory and invasive properties of placental cells and those of cancer …

[HTML][HTML] Progress and challenges in screening for early detection of ovarian cancer

IJ Jacobs, U Menon - Molecular & Cellular Proteomics, 2004‏ - Elsevier
Ovarian cancer is characterize by few early symptoms, presentation at an advanced stage,
and poor survival. As a result, it is the most frequent cause of death from gynecological …

Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum

JB Welsh, LM Sapinoso, SG Kern, DA Brown… - Proceedings of the …, 2003‏ - pnas.org
Genetic alterations in tumor cells often lead to the emergence of growth-stimulatory
autocrine and paracrine signals, involving overexpression of secreted peptide growth …